HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aesthetic Medicine

613.053

-0.662-0.11%

Number of Gainers:7

Number of Losers:3

Number of Flat:3

PE:- -

High:624.136

Open:613.521

Low:611.698

Close:613.715

Loading ...

Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials

MT Newswires Live

EC Healthcare Completes Major Stake Disposal, Acquisition

MT Newswires Live

Miricor Enterprises - Unit Entered Facility Agreement With Bank for Trade Finance & Revolving Loan Facility up to HK$10 Mln

THOMSON REUTERS

Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment

MT Newswires Live

Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules

MT Newswires Live

BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules

BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake

Anhui Sunhere Says Shareholder Shanghai Fosun Pharmaceutical Plans to Unload up to 3% Stake in Three Months

THOMSON REUTERS

Fosun Pharma Unit to Boost Stake in Medical Services Firm with Additional Investment

MT Newswires Live

Pinning Down Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) P/S Is Difficult Right Now

Simply Wall St.

Angelalign Technology's Subsidiary to Purchase Raw Materials for Aligner Production

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":613.0531,"timestamp":1741233599007,"preClose":613.71533,"halted":0,"volume":37360472,"delay":0,"changeRate":-0.001079,"change":-0.662231,"pbRate":1.187551,"amount":247129218,"amplitude":0.020266,"prevYearClose":571.87146,"fiveDayClose":630.978,"twentyDayClose":569.947,"turnoverRate":0.001865,"marketCap":110652552104,"floatMarketCap":72903228712,"peRate":21.508467},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":624.1355,"amplitude":0.020266,"preClose":613.71533,"low":611.6978,"pbRate":"1.187551","latestPrice":613.0531,"volume":37360472,"delay":0,"open":613.5211,"prevYearClose":571.87146,"prevWeekClose":612.07,"prevMonthClose":612.07,"prevQuarterClose":571.871,"fiveDayClose":630.978,"twentyDayClose":569.947,"sixtyDayClose":585.06,"secType":"PLATE","market":"HK","turnoverRate":0.001865,"peRate":21.508467,"marketCap":110652552104,"floatMarketCap":72903228712,"timestamp":1741233599007,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":7,"down":3,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516768536","title":"Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516768536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516768536?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:07","pubTimestamp":1741093665,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's   subsidiary Fosun Adgenvax  Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.Fosun Adgenvax  Biopharmaceutical plans to start the first phase of clinical trials in China.The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","02196","BK0239","BK1593","BK0096","BK0028","BK0012","BK0187","BK0188","BK0196","BK1191","BK0175","00656","BK1515","BK0060","BK0183"],"gpt_icon":0},{"id":"2516508022","title":"EC Healthcare Completes Major Stake Disposal, Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2516508022","media":"MT Newswires Live","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516508022?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:06","pubTimestamp":1740985570,"startTime":"0","endTime":"0","summary":"EC Healthcare's  subsidiary, Jade Master International, completed the sale of its 51% stake in New Medical Centre to AIA Hong Kong Medical Services on Friday, a Monday Hong Kong bourse filing said.The transaction was first announced in November 2024, with Jade Master agreeing to dispose of the majority stake for HK$437.6 million.The company also completed the acquisition of a 40% stake in its unit, Hong Kong Medical Advanced Imaging , as part of an internal reorganization within the group.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TST","BK1511","02138","BK1593","BK4201","SES.SI","HCSG","BK1215","BK4137","EC"],"gpt_icon":0},{"id":"2514103713","title":"Miricor Enterprises - Unit Entered Facility Agreement With Bank for Trade Finance & Revolving Loan Facility up to HK$10 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514103713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514103713?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:49","pubTimestamp":1740732577,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01827","BK1593","BK1215"],"gpt_icon":0},{"id":"2514393555","title":"Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514393555","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514393555?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:07","pubTimestamp":1740715674,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Xingsheng Xinhui Pharmaceutical received approval from China's medical products administrator to conduct clinical trials for a colorectal cancer drug.Specifically, the approval was for trials using XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for the treating RAS-mutated metastatic colorectal cancer, according to a Thursday filing with the Shanghai bourse.Xingsheng Xinhui plans to initiate Phase Ib/II clinical trials for this treatment regimen in mainland China once conditions are met.Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK1230","02196","BK0188","BK0239","BK0096","BK0187","BK0196","BK0028","BK1515","BK1593","00656","600196","BK0183","BK0012","BK0175","BK1191"],"gpt_icon":0},{"id":"2514434848","title":"Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514434848","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514434848?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:58","pubTimestamp":1740628689,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained marketing authorization for tenapanol hydrochloride tablets from China's food and drug administrator.The drug is used to control serum phosphorus levels in adult dialysis patients with chronic kidney disease who have inadequate response or intolerance to phosphate binders, according to a Thursday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0239","BK0187","00656","BK0096","BK1191","BK0028","BK1593","BK0175","02196","BK0060","BK1515","BK0183","BK0012","BK0188","600196"],"gpt_icon":0},{"id":"2514319348","title":"Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514319348","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514319348?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:21","pubTimestamp":1740572493,"startTime":"0","endTime":"0","summary":"China approved Shanghai Fosun Pharmaceutical  subsidiary Shanghai Fosun Pharmaceutical Industrial Development's tenapanor hydrochloride tablets for an indication of chronic kidney disease, according to a Wednesday filing with the Hong Kong Exchange.The tablets help control serum phosphorus levels in dialysis patients with chronic kidney disease who do not have an adequate response to phosphorus binders, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0239","BK0188","BK0012","BK1191","BK0175","BK0060","BK1515","02196","BK0183","BK0096","BK1593","BK0028","00656","BK0187","600196"],"gpt_icon":0},{"id":"2514675831","title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514675831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514675831?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:18","pubTimestamp":1740572317,"startTime":"0","endTime":"0","summary":"China accepted Shanghai Fosun Pharmaceutical  subsidiary Yaopharma's drug registration application for its bromhexine hydrochloride injection, according to a Wednesday filing with the Hong Kong Exchange.The drug is an expectorant indicated for lung ailments such as pulmonary tuberculosis, pneumoconiosis, or postoperative sputum retention, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","600196","BK1515","BK0239","BK0096","BK0060","02196","BK0028","BK0196","BK0012","BK0187","BK1593","00656","BK0188","BK1191","BK0183"],"gpt_icon":0},{"id":"2514315528","title":"Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514315528","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514315528?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:17","pubTimestamp":1740572245,"startTime":"0","endTime":"0","summary":"China granted Shanghai Fosun Pharmaceutical  subsidiary Suzhou Erye Pharmaceutical marketing approval for its compound sodium picosulfate granules for colon cleansing.The drug contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, and is used to clean the colon for colonoscopy or X-rays, and for preparation for colon surgery, according to a Wednesday filing with the Hong Kong Exchange.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0196","600196","BK0060","02196","BK0175","BK0183","BK1593","BK0012","BK0028","BK0187","BK0188","BK1191","BK0239","00656","BK1515"],"gpt_icon":0},{"id":"2514898880","title":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898880","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898880?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:31","pubTimestamp":1740565889,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate GranulesFeb 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED MARKETING REGISTRATION APPROVAL FROM NMPA CHINA FOR COMPOUND SODIUM PICOSULFATE GRANULESFurther company coverage: 600196.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","BK1191","BK1515","BK0183","BK0012","02196","BK0187","BK0196","600196","BK0096","BK0028","BK0060","BK0175","BK1593"],"gpt_icon":0},{"id":"2513730498","title":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2513730498","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513730498?lang=en_us&edition=fundamental","pubTime":"2025-02-23 21:31","pubTimestamp":1740317465,"startTime":"0","endTime":"0","summary":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake Feb 23  - Anhui Sunhere 300452.SZ:SAYS SHAREHOLDER SHANGHAI FOSUN PHARMACEUTICAL PLANS TO UNLOAD UP TO 3% STAKE IN THREE MONTHSSource textFurther company coverage: 300452.SZ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nL3N3PE02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0177","BK0183","BK0187","BK0196","BK0096","BK1593","BK0060","BK0188","BK1515","600196","BK0175","BK0028","300452","02196","BK0012","BK0239"],"gpt_icon":0},{"id":"2513304677","title":"Anhui Sunhere  Says Shareholder Shanghai Fosun Pharmaceutical Plans to Unload up to 3% Stake in Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2513304677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513304677?lang=en_us&edition=fundamental","pubTime":"2025-02-23 21:31","pubTimestamp":1740317465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nL3N3PE02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0177","BK0028","BK0196","BK0187","300452","BK0096","BK0188","600196","BK0060","BK1515","BK1593","BK0175","BK0183","BK0012","BK1191","02196"],"gpt_icon":0},{"id":"2513256688","title":"Fosun Pharma Unit to Boost Stake in Medical Services Firm with Additional Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2513256688","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513256688?lang=en_us&edition=fundamental","pubTime":"2025-02-21 16:23","pubTimestamp":1740126196,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Shanghai Fosun Health Technology will inject 30 million yuan into Shanghai Zhuoerhui Integrated Outpatient.The capital contribution will mainly be to support the target company's daily operations and the construction of its disciplines, branding, and marketing system.Following completion, Fosun Health's shareholding in the target will rise to 67.1872% from 57.5363%, a Thursday filing with the Hong Kong bourse said.Shanghai Zhuoerhui Integrated Outpatient mainly provides medical services such as physical examination and general and specialist outpatient clinics.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0196","600196","BK0060","02196","BK0175","BK0183","BK1593","BK0012","BK0028","BK1230","BK0187","BK0188","BK1191","BK0239","00656","BK1515"],"gpt_icon":0},{"id":"2513239825","title":"Pinning Down Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) P/S Is Difficult Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2513239825","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513239825?lang=en_us&edition=fundamental","pubTime":"2025-02-21 08:10","pubTimestamp":1740096618,"startTime":"0","endTime":"0","summary":"When you see that almost half of the companies in the Pharmaceuticals industry in Hong Kong have price-to-sales ratios...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-460/sihuan-pharmaceutical-holdings-group-shares/news/pinning-down-sihuan-pharmaceutical-holdings-group-ltds-hkg46","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","00460","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2512411928","title":"Angelalign Technology's Subsidiary to Purchase Raw Materials for Aligner Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2512411928","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512411928?lang=en_us&edition=fundamental","pubTime":"2025-02-20 17:42","pubTimestamp":1740044573,"startTime":"0","endTime":"0","summary":"Angelalign Technology's  subsidiary Wuxi EA Medical Instruments Technologies agreed to purchase certain raw materials from Shanghai Maxflex Medical Technology, a Wednesday bourse filing said.The materials will be used for the production of clear aligners.The annual caps set for the transaction are 30 million yuan for 2025, 42 million yuan for 2026, and 58.8 million yuan for 2027.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK1587","BK4544","06699","BK1100","ARKG","BK4585","BK1583","BK4588"],"gpt_icon":0}],"pageSize":16,"totalPage":1,"pageCount":1,"totalSize":14}]}}